Unknown PHASE3 INTERVENTIONAL 2-arm NCT05334238

Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

A Multi Center, Randomized, Controlled Clinical Study of the Efficacy and Safety of Orelabrutinib Maintenance Therapy After ASCT in Patients With Primary Central Nervous System Lymphoma

Sponsor: Ruijin Hospital

Conditions Primary Central Nervous System Lymphoma

Interventions Orelabrutinib

Updated 4 times since 2022 Last updated: Apr 18, 2022 Started: Dec 1, 2021 Primary completion: May 30, 2024 Completion: May 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Primary Central Nervous System Lymphoma, this trial is ongoing. The trial is conducted by Ruijin Hospital and has accumulated 4 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Jun 2025 — Present [monthly]

Unknown PHASE3

Status: Recruiting → Unknown
Sep 2024 — Jun 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
May 2022 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ruijin Hospital

Data source: Ruijin Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China